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Abstract 
Background: Malaria caused by Plasmodium vivax and Plasmodium falciparum is among the major public health 
problems in most endemic areas of the world. Artemisinin-based combination therapy (ACT) has been recom-
mended as a first-line treatment for uncomplicated Plasmodium falciparum malaria almost in all endemic regions. 
Since ineffectively regulated medicines in resource limited settings could favour infiltration of poor quality anti-
malarial medicines into pharmaceutical supply chain and jeopardize a positive treatment outcome, regular monitor-
ing of the quality of anti-malarial medicines is critical. Thus, the aim of this study was to assess the quality of fixed dose 
combination (FDC) artemether (ART)/lumefantrine (LUM) tablets available in Jimma zone, Ethiopia.
Methods: This study was conducted in Jimma zone, Ethiopia. A total of 74 samples of FDC ART/LUM (20 mg 
ART/120 mg LUM) tablets were collected from 27 public facilities. All samples were subjected to visual inspection and 
the relevant information was recorded. The samples were transported to Jimma University Laboratory of Drug Quality 
(JuLaDQ) and stored at ambient temperature (20 °C to 25 °C) until analysis. The Pharmacopoeial conform/non-con-
form methods and the risk-based Derringer’s desirability function approach were employed to assess the pharmaceu-
tical quality of the investigated products.
Results: The visual inspection results revealed that there were no signs of falsified in the investigated products. 
Identification test results of samples indicated that all samples contained the stated active pharmaceutical ingredients 
(APIs). The results of uniformity of mass indicated that all samples complied with International Pharmacopoeial specifi-
cation limits. The assay results, expressed as percent label claim (%lc) of ART (89.8 to 108.8%, mean ± SD = 99.1 ± 3.9%) 
and LUM (90.0 to 111.9%, mean ± SD = 98.2 ± 3.8%) revealed that, all samples complied with International Pharma-
copoeia acceptance specification limits (i.e. 90–110%lc), except one generic product (IPCA Laboratories Ltd., India) 
which contains excessive LUM (111.9 ± 1.7%lc). The risk priority number (RPN) results revealed that assay (RPN = 392) 
is relatively the most critical quality attribute followed by identity (RPN = 280) and mass uniformity (40). Quality evalu-
ation based on psycho-physical Harrington’s scale revealed that more than 96% of samples were within the accept-
able ranges (D ≥ 0.7–1.0).
Conclusions: Both Pharmacopoeial and risk-based desirability function approaches to quality evaluation applied to 
the investigated products revealed that above 96% FDC ART/LUM tablets circulating in public settings of Jimma zone 
are of good quality.
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Background
Malaria is the major public health problem in Africa 
which accounts for 90% of all malaria cases and 92% of 
deaths ascribed to malaria in the world [1]. Interven-
tions such as use of anti-malarial medicines, insecticide-
treated bed nets and indoor residual sprays have been 
employed in malaria endemic areas [2–7] and reduced 
malaria prevalence by 50% and clinical incidence by 40% 
between 2000 and 2015 [3]. However, prevalence of poor 
quality anti-malarial medicines [8–10] linked to reduced 
efficacy, treatment failure or death [11–13] and insecti-
cide resistance of malaria transmitting mosquitoes [14, 
15] are obstacles potentially threatening the global target 
to eliminate incidence of malaria infection [16].
In Ethiopia, malaria infection caused by Plasmodium 
vivax and Plasmodium falciparum is a common problem 
that affects a large number of people living in malaria-
endemic areas [17, 18]. Thus, to reduce mortality and 
morbidity due to malaria, fixed dose combination (FDC) 
artemether (ART)/lumefantrine (LUM) and chloro-
quine have been used as first-line treatment for malaria 
caused by Plasmodium falciparum and Plasmodium 
vivax, respectively [19]. Since poor quality [i.e. falsified 
(medical products that deliberately/fraudulently mis-
represent their identity, composition or source) or sub-
standard (authorized medical products that fail to meet 
either their quality standards or their specifications, or 
both) of anti-malaria medicines is one of the risk factors 
that could affect the intended clinical outcomes, ensur-
ing the quality of medicines is crucial in providing quality 
health care services. In Ethiopia, though there are previ-
ous studies indicating the occurrence of poor quality of 
anthelminthic, anti-protozoal and non artemisinin-based 
combination therapy (ACT) anti-malarial medicines [20–
24], no evidenced information is found on the quality of 
FDC ART/LUM products. Thus, evaluating the quality of 
FDC ART/LUM products circulating in the health facili-
ties is critical to reduce risk of having poor quality medi-
cines. Therefore, the aim of this study was to assess the 
pharmaceutical quality of FDC ART/LUM tablets avail-
able in Jimma zone, Oromia Regional state, Ethiopia.
Methods
Study area
The study was conducted in all districts of Jimma zone, 
Oromia Regional State. The areas were selected due to 
the fact that they are endemic for malaria. In Ethiopia, 
patients can get FDC ART/LUM products free of charge 
from public health centres and hospitals. Thus, these 
products are less likely to be dispensed in private drug 
retail outlets. Therefore, all government owned public 
facilities (health centre, hospitals and wholesales) operat-
ing in the study area were included in this study. Jimma is 
the commercial hub for the south west Ethiopia and thus 
relatively huge pharmaceutical transaction occurs in the 
region. Currently, there are 7 wholesales (all of them in 
Jimma city), 71 drug shops (31 in Jimma city and 40 in 
districts of Jimma zone), 101 public drug shops in health 
centres (3 in Jimma city and 98 in districts of Jimma 
zone), 18 private pharmacies (all of them in Jimma city) 
and 4 hospital pharmacies in Jimma zone. The map of 
Jimma zone, Oromia Regional State is presented in Fig. 1.
Chemicals/reagents/solvents
Artemether (99% w/w) and lumefantrine (99% w/w) 
working standard active pharmaceutical ingredients 
(APIs) were supplied by Dafra Pharma International 
(B-2300 Turnhout, Belgium) through Drug Quality and 
Registration (DruQuaR) laboratory, University of Ghent, 
Belgium. Ultrapure water (18.2  MΩ  cm at 25  °C) was 
prepared in Jimma University Laboratory of Drug Qual-
ity (JuLaDQ) using ultrapure water purification system 
(Thermofischer Scientific, USA). Methanol (HPLC grade, 
Fisher Scientific), acetonitrile (HPLC grade, Fisher Scien-
tific), ethyl acetate and acetone (Fisher Scientific), glacial 
acetic acid and sulfuric acid (Reagent Chemical Services), 
sodium hexanesulfonate (Fluka Analytical, Germany) and 
sodium dihydrogen phosphate (Reagent Chemical Ser-
vices) were used as received.
Sample collection
The quality survey was conducted by considering the 
guidelines for field surveys of the quality of medicines 
proposed by Newton et  al. [25]. A total of 74 FDC 
ART/LUM (20 mg ART/120 mg LUM) tablets samples 
were collected between May and June, 2013 from all 
public health facilities (where available) [wholesales 
(n = 2), hospital pharmacy (n = 1) and health centre 
drug stores (n = 24)] operation in Jimma zone. Sam-
ple with different products names (i.e.  Coartem® = 35 
and generic = 39) and countries of origin [Ethiopia 
(n = 1), China (n = 1), India (n = 38) and USA (n = 34)] 
were collected anonymously by mystery shoppers from 
local area who were trained before to present a con-
firmed P. falciparum malaria patient of 25 years of age 
with a prescription stating 4 tablets twice per day for 
3 consecutive days (full adult dose of 24 tablets). The 
mystery shoppers were blinded about the purpose of 
Keywords: Quality, Anti-malarials, Artemether, Lumefantrine, Jimma, Ethiopia
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the study and only instructed to collect samples. The 
relevant information of all collected samples (level of 
drug outlet, place of collection, name of APIs, country 
of origin, manufacturing company, expiry date, manu-
facturing date, batch/lot number and strength of APIs) 
was recorded on standard form as soon as leaving the 
drug outlet and entered into database. The samples 
were transported to JuLaDQ and stored at ambient 
temperature (20 °C to 25 °C) until analysis.
Physico‑chemical quality assessment
All samples were visually inspected for physical char-
acteristics of tablets (i.e. shapes, colour, breaks, cracks 
and splits), packaging and labelling information (i.e. 
name of the active pharmaceutical ingredient, the 
country of origin, manufacturing company, expiry 
date, manufacturing date, batch/lot number, number 
of units per strip/package and labelled dose (strength) 
of the active ingredient) using the checklist set by 
WHO [26]. The modified checklist is presented in 
Additional file 1.
Identification tests
The presence of ART and LUM APIs in FDC ART/LUM 
tablets was analysed according to the method given in 
the International Pharmacopoeia [27]. In addition, thin 
layer chromatography, chromatographic peak retention 
time and DAD-UV absorption spectra were used for the 
purpose of identification through comparison with reten-
tion time and DAD-UV absorption spectra of the peak 
obtained on a working standard solutions of ART and 
LUM APIs.
Uniformity of mass
The mass uniformity test of tablet samples was conducted 
according to the method given in the International Phar-
macopoeia [28]. Randomly selected tablets (n = 20) of 
each sample were individually weighed with a calibrated 
balance (Mettler Toledo, AL204-1C, Switzerland) with an 
accuracy of 0.006%. The uniformity of mass of the tablet 
samples was evaluated against Pharmacopoeial specifica-
tion (i.e. the deviation of individual masses of minimum 
of 18 and maximum of 2 tablets should not exceed 
by ± 7.5% and ± 15% from average mass, respectively).
Fig. 1 Map of Jimma zone, Oromia Regional State
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Assay of active substance in the tablet samples
The amount of ART and LUM APIs in samples of 
FDC ART/LUM tablets was determined based on the 
method given in an individual monograph of Interna-
tional Pharmacopoeia [29].
System suitability
System suitability was evaluated according to the Euro-
pean Pharmacopoeia method [30]. The symmetry fac-
tor  (As) of principal peaks was calculated using the 
following formula:
where  Wx = peak width at 5% of reference standard peak 
height measured from the base line, d = base line dis-
tance between the perpendicular dropped from the peak 
maximum and the leading edge of the peak at 5% of peak 
height measured in the same unit as  Wx. The specifica-
tion was an  As value of maximally 1.5. In addition, per-
cent relative standard deviation (%RSD) of replicate 
injections (n = 6) of reference standards were calculated 
and compared against the European Pharmacopoeia 
specification limit, i.e. %RSD of sextuplicate injections 
should be maximally 2.
Mobile phase preparation
The mobile phases 70/30% v/v (A) and 30/70% v/v (B) 
ion pair reagent/acetonitrile (HPLC grade, Fisher Sci-
entific) were prepared for gradient elution. Ion-pair 
reagent was prepared by dissolving 5.65  g of sodium 
hexanesulfonate (Fluka Chemicals Ltd.) and 2.75  g of 
sodium dihydrogen phosphate (Fishers Scientific) in 
900.0 ml of ultra-pure water (18.2 MΩ cm) and adjusted 
to pH 2.3 using phosphoric acid (ReAgent Chemicals, 
UK), diluted to volume (1000.0 ml) and filtered through 
a 0.45 µm filter (Macherey–Nagel, Germany).
Working standard solution
Working standards of ART (20 mg) and LUM (120 mg) 
were individually added into 100.0 ml volumetric flask, 
dissolved in 85  ml of solvent (i.e. ion pair/ultra-pure 
water/1-propanol/acetonitrile: 20/6/20/54% v/v), soni-
cated, allowed to cool to room temperature and diluted 
to volume.
Sample solution
Twenty tablets of each sample were randomly selected 
and powdered. A portion of powder equivalent to 
20  mg ART and 120  mg LUM was individually added 
into 100.0  ml volumetric flask, dissolved in 85.0  ml of 
solvent (i.e. ion-pair/ultra-pure water/1-propanol/
As =Wx/2d
acetonitrile: 20/6/20/54% v/v), sonicated (20  min), 
allowed to cool to room temperature and diluted to 
volume.
HPLC method
The analysis of samples was conducted using Agilent 
1260 Infinity Series HPLC system (Agilent Technolo-
gies, Santa Clara, California, USA) equipped with a C18 
column  (Symmetry®) (150  mm × 3.9  mm, 5  μ particle 
size) coupled to a diode-array detector (DAD). The sam-
ple temperature in auto-injector was 25  °C. The column 
temperature, flow rate, injection volume, run time were 
25 °C, 1.3 ml/min, 20 µl and 55 min, respectively.
Risk analysis
Failure mode effects analysis (FMEA) was used to evalu-
ate criticality of product quality attributes. Criticality was 
evaluated based on risk priority number (RPN) which 
considered occurrence, severity and detection of the fail-
ure and calculated using the formula:
where O, S and D denote the occurrence of a failure 
mode, the severity of a failure effect, and the probability 
of not detecting the failure, respectively [31].
The scales used for scoring severity, occurrence and 
detectability are presented in Tables 1, 2, 3.
Pharmaceutical experts working at JuLaDQ (n = 3) 
and Ethiopian Food and Drug Authority (EFDA) (n = 2) 
were assigned to score for severity, occurrence and 
detectability. The potential effect of each failure mode 
was considered to assign a severity rating. Thus, the 
RPN = O × S × D
Table 1 Traditional FMEA scale for  occurrence. Source: 
Ford Motor Company. Potential Failure Mode and Effects 
Analysis (FMEA) Reference Manual; Ford Motor Company: 
Dearborn, MI, USA, 1988. https ://www.world cat.org/title 
/poten tial-failu re-mode-and-effec ts-analy sis-fmea-refer 
ence-manua l/oclc/43210 773
Probability of failure Possibility of failure rates Rank
Extremely high: failure 
almost inevitable
≥ 1 in 2 10
Very high 1 in 3 9
Repeated failures 1 in 8 8
High 1 in 20 7
Moderately high 1 in 80 6
Moderate 1 in 400 5
Relatively low 1 in 2000 4
Low 1 in 15,000 3
Remote 1 in 150,000 2
Nearly impossible ≤ 1 in 1,500,00 1
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score of 10, 8 and 5 was assigned for identity, assay and 
mass uniformity, respectively. Literature data on preva-
lence of substandard and/or falsified anti-malarial med-
icines in Africa [8–10, 32] and the findings from this 
study were used to assign scores for occurrence. There-
fore, the occurrence score of 7, 7 and 4 were assigned 
for identity, assay and uniformity of mass, respectively. 
Detecting defects of the mass uniformity and identity 
is relatively easy and does not require high technol-
ogy facility, advanced knowledge and skills. Therefore, 
detectability score of 4 and 2 was assigned for identity 
and mass uniformity, respectively. On the other hand, 
since assay requires fully equipped laboratory system 
and advanced training of personnel, detectability score 
of 7 was assigned for assay. The assigned scores for 
severity, occurrence and detectability are presented in 
Additional file 2.
Desirability function
Derringer’s desirability function [23, 33] was applied to 
assess quality of the evaluated product. The overall desir-
ability function (D) value which is the geometric mean 
of the individual desirabilities  (di), indicates the product 
quality. The highest global desirability value represents 
the product with the highest quality. The D value was cal-
culated using the following formula:
where  pi is the weight or relative importance assigned to 
the response, n is the product quality attributes evalu-
ated,  di is an individual desirability. In this study, three 
product quality attributes (i.e. identity, assay and mass 
uniformity) were considered and thus n equals to 3 is 
n
√√√√
n∏
i=1
di
pi
Table 2 Traditional FMEA scale for  severity. Source: Ford Motor Company. Potential Failure Mode and Effects Analysis 
(FMEA) Reference Manual; Ford Motor Company: Dearborn, MI, USA, 1988. https ://www.world cat.org/title /poten tial-failu 
re-mode-and-effec ts-analy sis-fmea-refer ence-manua l/oclc/43210 773
Effect Criteria: severity of effect Rank
Hazardous Failure is hazardous, and occurs without warning. It suspends operation of the system 10
Serious Failure involves hazardous outcomes and/or noncompliance with government regulations or standards 9
Extreme Product is inoperable with loss of primary function. The system is inoperable 8
Major Product performance is severely affected but functions. The system may not operate 7
Significant Product performance is degraded. Comfort or convince functions may not operate 6
Moderate Moderate effect on product performance. The product requires repair 5
Low Small effect on product performance. The product does not require repair 4
Minor Minor effect on product or system performance 3
Very minor Very minor effect on product or system performance 2
None No effect 1
Table 3 Traditional FMEA scale for detection. Source: Ford Motor Company. Potential Failure Mode and Effects Analysis 
(FMEA) Reference Manual; Ford Motor Company: Dearborn, MI, USA, 1988. https ://www.world cat.org/title /poten tial-failu 
re-mode-and-effec ts-analy sis-fmea-refer ence-manua l/oclc/43210 773
Detection Criteria: likelihood of detection by design control Rank
Absolute uncertainty Design control does not detect a potential cause of failure or subsequent failure mode; or there is no design control 10
Very remote Very remote chance the design control will detect a potential cause of failure or subsequent failure mode 9
Remote Remote chance the design control will detect a potential cause of failure or subsequent failure mode 8
Very low Very low chance the design control will detect a potential cause of failure or subsequent failure mode 7
Low Low chance the design control will detect a potential cause of failure or subsequent failure mode 6
Moderate Moderate chance the design control will detect a potential cause of failure or subsequent failure mode 5
Moderately high Moderately high chance the design control will detect a potential cause of failure or subsequent failure mode 4
High High chance the design control will detect a potential cause of failure or subsequent failure mode 3
Very high Very high chance the design control will detect a potential cause of failure or subsequent failure mode 2
Almost certain Design control will almost certainly detect a potential cause of failure or subsequent failure mode 1
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taken in global evaluation of the investigated FDC ART/
LUM tablet samples. According to RPN value, which is 
the numeric assessment of risk assigned to each quality 
parameter, p value of 3, 2 and 1 was assigned for assay, 
identity and mass uniformity, respectively.
Modified psychophysical five interval scale of Har-
rington’s desirability function [34] was constructed and 
used as a tool for quality judgment; i.e. qualitative assess-
ments “bad”, “low”, “acceptable”, “good” and “excellent” 
which correspond to numeric intervals of 0.00–0.37, 
0.37–0.70, 0.70–0.80, 0.80–0.90, and 0.90–1.00, respec-
tively. The numeric desirability values of the quality 
attributes were considered as physical parameters; while 
the subjective judgments of the experts (i.e. excellent, 
good, acceptable, low or bad) were considered as psy-
chological. For assay a two-sided desirability function 
was used; and a one-sided desirability function was used 
for identity and mass uniformity. Since absence of API 
is assumed to be clinically completely undesirable, d =  0 
was assigned. While d =  1 was assigned for 100%lc which 
is assumed to be optimum desirability. Since assay of both 
ART and LUM APIs in FDC ART/LMU tablet should be 
from 90 to 110%lc [29] and psychophysical Harrington’s 
scale specifies desirability range from 0.70 to 1.00 to be 
good, d =  0.7 was assigned for assay values of 90 and 
110%lc and d =  0.3 was assigned for 70% and 130%lc. 
While d =  0.01 was assigned for 50% and 150%lc. The 
individual desirability function for assay was then defined 
as different linear sections of different slopes in the 
range of 100%lc to 90%lc (slope =  0.03), 90%lc to 70%lc 
(slope =  0.02) and from 70%lc to 50%lc (slope =  0.01).
For mass uniformity, the relative standard deviation 
(RSD) was considered as response. According to Euro-
pean Pharmacopoeia [28], RSD should not be more than 
2% and thus d =  1, d =  0.7, d =  0.3, d = 0.01 and d = 0 
were assigned for RSD of 0, 2, 6, 15 and 25%, respec-
tively. For identity, d =  1.0 was assigned for samples com-
plied with Pharmacopoeia specification. While d = 0 was 
assigned for those which do not comply.
Results
A total of 74 samples (i.e.  Coartem® = 35,  Artefan® = 6, 
 Artemine® = 1, and artemether–lumefantrine = 32) were 
collected between May to June, 2013 from wholesales 
(n = 2), hospitals (n = 4) and health centres (n = 68).
The results of visual inspection of samples for physical 
characteristics of tablets, packaging and labelling infor-
mation as set by WHO revealed that there were no signs 
of falsified in the investigated products. Detail informa-
tion of samples on physical characteristics of tablets, 
packaging and labelling information is presented in Addi-
tional file 3.
Identification test results of samples revealed that all 
samples had the intended APIs as demonstrated by the 
positive identification tests. Consistent results were 
obtained with the Pharmacopoieal methods, thin-layer 
chromatography, HPLC retention and DAD information.
The results of uniformity of mass indicated that all 
samples complied with International Pharmacopoeia 
specification limits (i.e. the deviation of individual masses 
of minimum of 18 and maximum of 2 tablets should not 
exceed by ± 7.5% and ± 15% from average mass, respec-
tively). The mass %deviation distributed among brand 
products are presented in Table 4.
The results of amount of ART and LUM in the FDC 
ART/LUM tablet samples revealed that except one 
generic product (IPCA Laboratories Ltd., India) which 
failed to comply (111.9%lc) for LUM API, all samples 
complied with the Pharmacopoieal acceptance specifi-
cation limit [i.e. 90.0–110.0% (percent label claim (%lc)]. 
The amount of ART API in samples analysed ranges 
from 89.8 to 108.8% (mean: 99.1%, SD: 3.9%), while 
that of LUM ranges from 90.0 to 111.9% (mean: 98.2%, 
SD: 3.8%). The amount of ART and LUM APIs in FDC 
ART/LUM tablet samples collected from health centre 
(ART = 89.78–105.92%, LUM = 91.19–111.87%), hos-
pitals (ART = 97.70–101.94%, LUM = 90.03–104.24%) 
and wholesales (ART = 100.52–108.78%, LUM = 93.68–
107.98%) indicated relative differences in the amount 
of ART/LUM APIs among investigated products. The 
results of the amount (%lc) of ART and LUM APIs in 
FDC ART/LUM tablet samples are presented in Addi-
tional file  4. Amount (%lc) of ART and LUM APIs dis-
tributed among brand and generic product is given in 
Table 5.
Risk analysis
The results of the RPN are presented in Table  6. Assay 
(RPN =  392) is the most critical quality attribute followed 
by identity (RPN =  280) and mass uniformity (RPN = 40).
Derringer’s desirability function
The results of individual desirability values  (di) and the 
overall desirability (D) are presented in Additional file 5. 
Table 4 Results of  mass %deviation distributed 
among brand products of FDC ART/LUM tablets
# Product name (n) %Deviation
Minimum Maximum Mean
1 Coartem® (35) 0.75 7.11 1.61
2 Artemether–lumefantrine (32) 0.80 2.64 1.78
3 Artefan® (6) 0.99 4.5 2.55
4 Artemine® (1) 1.34 1.34 1.34
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The individual desirability values assigned to the differ-
ent segments were fitted to the segmented linear model 
as presented in Fig. 2.
A global D-value of investigated products was cal-
culated using d-functions of quality attributes (i.e. 
identity, assay and mass uniformity). Since FDC ART/
LUM tablet contains FDC 20  mg ART and 120  mg 
LUM APIs, d-functions of identity and assay for ART 
and LUM were calculated individually. Based on Har-
rington’s scale of quality, 96% of the investigated prod-
ucts were within acceptable range (D = 0.7–1.0). The 
Table 5 Amount (%lc) of ART and LUM APIs distributed among brand and generic products
SD standard deviation, NA not applicable
# Product name (n) API %lc
Minimum Maximum Mean SD Median
1 Coartem® (35) ART 90.9 103.6 98.9 3.0 99.6
LUM 90.0 104.1 97.4 3.4 97.7
2 Artemether–lumefantrine (32) ART 91.5 106.7 99.2 4.3 99.7
LUM 93.6 111.9 98.8 3.8 98.7
3 Artefan® (6) ART 89.8 103.4 98.2 5.0 99.4
LUM 91.2 104.2 98.7 4.7 99.6
4 Artemine® (1) ART 108.8 108.8 108.8 NA 108.8
LUM 108.0 108.0 108.0 NA 108.0
Table 6 Failure mode and effect analysis for FDC ART/LUM tablet quality attributes
RPN risk priority number
Critical quality attributes Failure mode Failure effects Severity Occurrence Detection RPN
Identity No (intended) active ingredient in the 
sample or mislabelling (incorrect, 
inadequate or incomplete identi-
fication)
Treatment failure, death due to 
untreated disease, toxicity
10 7 4 280
Assay Under-dose, over-dose Treatment failure, toxicity due to 
over-dose, drug resistance due to 
under-dose
8 7 7 392
Uniformity of mass Non-uniform distribution of dose/
content within the individual dos-
age units
Sub-optimal therapy for a patient tak-
ing the sub-standard dosage unit 
and drug resistance
5 4 2 40
Fig. 2 Linear desirability functions: a assay and b mass uniformity
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results of quality evaluation based on modified psycho-
physical Harrington’s scale of quality are presented in 
Table 7.
Discussion
In this study, the pharmaceutical quality of FDC ART/
LUM tablets was assessed. The results of visual inspec-
tion on physical characteristics of tablets, packaging and 
labelling information revealed that none of the samples 
demonstrated signs of falsified as defined by the WHO 
[35]. In addition, packaging of the investigated products 
complied with the WHO guideline on packaging for 
pharmaceutical products [36]. Appropriate packaging is 
important to protect the pharmaceutical products from 
environmental and transportation stress which are risk 
factors for product quality defects. Thus, the investigated 
products might not have a risk of stability problems asso-
ciated with packaging [37].
The identity test results indicated that none of the sam-
ples contained incorrect APIs which revealed that due to 
the investigated products there was no risk of treatment 
failures or death [38–40]. The study results indicated that 
the investigated products complied with mass uniform-
ity specification set in International Pharmacopoiea for 
uncoated and film-coated tablets formulated to contain 
5% or more of the active ingredient (i.e. the deviation of 
individual masses of minimum of 18 and maximum of 2 
tablets should not exceed by ± 7.5% and ± 15% from aver-
age mass, respectively) [28]. This suggests that variations 
observed in mass among dose units in each batch might 
not affect the content uniformity of the dose units of the 
investigated products as mass uniformity is an alternative 
test for content uniformity of uncoated and film coated 
tablets.
The results of amount of APIs indicated that majority 
(98.6%) of investigated products comply with Pharmaco-
poeial specification limit (i.e. %lc = 90–110%) [29]. Only 
one generic product contain excess LUM API (111.7%lc) 
and thus failed to comply with International Pharmaco-
poeia (Ph. Int.) specification. The results of amount of 
APIs suggest that the dose units of majority of the inves-
tigated products contain sufficient levels of both ART 
and LUM APIs and could not have a risk of treatment 
failure [12, 40–42], longer parasite clearance time and 
greater recrudescence [43, 44] and emergence of resist-
ance [13]. Though effectiveness of medicines depends 
on various factors such as food intake, age, nutritional 
status, pharmacokinetic and IC50 of parasites [45, 46], 
sufficient amount of ART and LUM APIs observed in 
majority of the investigated products is very critical to 
reduce asexual parasite mass, eliminate the residual 
parasites and prevent recrudescence [47] and augment 
the recommended parasitological and clinical cure rate 
(≥ 90%) [48] The presence of excess LUM API (111.7%lc) 
in one generic product having the same batch number 
with the products which contain LUM API ranging from 
96.1 to 102.0%lc could be attributed to excipient particle 
size, blending techniques or processing parameters that 
could influence product quality [49]. This points to poor 
adherence to Good Manufacturing Practice (GMP).
According to the WHO, multisource products must 
satisfy the same standards of quality, safety and efficacy 
applied to the corresponding innovator product [50]. In 
this study, majority of investigated products qualify Phar-
macopoeial specification limits set for amount of API. 
Thus, interchangeable use of these products may not 
have a risk arising from amount of APIs.
The use of poor quality anti-malarial medicines could 
have a risk of reduced efficacy, an increased development 
of drug resistance, prolonged and more severe illness or 
unexpected adverse effects [11, 12, 32, 42, 43, 51]. There-
fore, evaluating criticality of product quality attributes 
for efficacy using risk analysis method is crucial for risk 
mitigation strategies. To this end, failure mode effects 
analysis (FMEA) method [52] was used and the risk asso-
ciated with each failure mode (identity, assay or mass 
uniformity) was evaluated based on the values of RPN. 
As a result, assay (RPN = 392) is found to be the most 
critical quality attribute followed by identity (RPN = 280) 
and mass uniformity (RPN = 40). This implies that quality 
risk with regard to assay is relatively higher.
Compared to conventional (Pharmacopoieal) method 
of quality verification, risk-based desirability function 
approach to quality evaluation provides more weight 
to the clinically more critical quality attributes. For 
Table 7 Modified psycho-physical Harrington’s scale 
of quality
# Interval in global 
desirability
Quality, 
descriptive 
evaluation
Percent of products 
in each quality scale
ART in FDC ART/LUM tablets
 1 0.90–1.00 Excellent 47.3
 2 0.80–0.90 Good 31.1
 3 0.70–0.80 Acceptable 20.3
 4 0.37–0.70 Low 1.4
 5 0.00–0.37 Bad –
LUM in FDC ART/LUM tablets
 1 0.90–1.00 Excellent 39.2
 2 0.80–0.90 Good 36.5
 3 0.70–0.80 Acceptable 20.3
 4 0.37–0.70 Low 4.1
 5 0.00–0.37 Bad –
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products having various quality characteristics, the qual-
ity of the product is completely unacceptable if one of 
the characteristics lies outside the desired limits. In this 
study, the quality of investigated products was evalu-
ated based on calculated D values compared against 
constructed numeric intervals ranging between 0 and 1. 
Thus, qualitative assessments of the investigated prod-
ucts (bad, low, acceptable, good and excellent) which cor-
respond to respective numeric intervals were conducted 
based on modified psycho-physical Harrington’s scale of 
quality. Based on the results obtained from risk based 
desirability approach of quality evaluation and consider-
ing ART and LUM APIs, 96% and 98.7% of the quality 
of the investigated products lie within acceptable range 
(0.70–1.00), respectively. The results of risk-based desir-
ability approach quality evaluation are in-line with the 
results (98%) observed in Pharmacopoeial (conform/
non conform) quality verification approach. Since using 
of risk based desirability approach provides more weight 
to clinically more critical quality attributes, this approach 
helps to make reliable decision based on clinically more 
critical quality attributes. In addition, it could be used 
to determine deviations from the desired response lev-
els. Moreover, risk based desirability approach of quality 
evaluation less heavily penalize marginal out-of specifi-
cation medicines and assumed to save economic loss in 
resource scarce society.
Conclusions
The results of this finding revealed that the quality of 
96–98% of the investigated products lies within accept-
ance limit when evaluated using both Pharmacopoeial 
and risk-based desirability function approaches. This sug-
gests that the medicines circulating in the public settings 
of Jimma zone are of good quality. However, this does not 
necessarily mean that there is effective regulatory system 
that helps to prevent infiltration of poor quality medi-
cines into pharmaceutical supply chain. Therefore, com-
plete nationwide survey which includes private settings 
should be done.
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